Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextrothyroxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 11/20 | 1.00 |
| ▸ | THRA known ✓ | P10827 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | PPARG | P37231 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | TTR | P02766 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextrothyroxine SCHEMBL30885760 | 1.00 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL11131863 | 1.00 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL3286699 | 1.00 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL26147 | 1.00 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL4575383 | 1.00 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL4997979 | 1.00 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL7944262 | 1.00 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Levothyroxine SCHEMBL23098 | 1.00 | THRB (1.00) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL11320096 | 0.99 | THRB (0.97) | THRBMEN1KMT2ATHRALMNA | |
| Thyroxine SCHEMBL2014581 | 0.99 | THRB (0.97) | THRBMEN1KMT2ATHRALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3769 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071218-A1 | Oral Delivery of Antisense Conjugates Targeting PCSK9 | CIVI BIOPHARMA INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-12421516-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2025-09-23 | — | — | US | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12291708-B2 | Oral delivery of antisense conjugates targeting PCSK9 | CIVI BIOPHARMA, INC. (US) | 2025-05-06 | — | — | US | claimed |
| CN-112263682-B | PCSK 9-targeting antisense oligomers and conjugates | 罗氏创新中心哥本哈根有限公司 | 2024-08-20 | — | — | CN | claimed |
| US-20240269066-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA | PRECVISION BIOTECHNOLOGIES LTD. (CN) | 2024-08-15 | — | — | US | claimed |
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-03-28 | — | — | US | claimed |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2024-03-14 | — | — | US | claimed |
| WO-1996040048-A2 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS | KARO BIO AB (SE) | 1996-12-19 | — | — | WO | claimed |
| EP-0732920-A1 | THERAPEUTIC AGENTS CONTAINING THYROID HORMONES | Knoll AG (DE) | 1996-09-25 | — | — | EP | claimed |
| EP-0457514-B1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | SQUIBB & SONS INC (US) | 1996-08-21 | — | — | EP | claimed |
| WO-1995020953-A1 | THERAPEUTIC AGENTS CONTAINING THYROID HORMONES | KNOLL AG (DE) | 1995-08-10 | — | — | WO | claimed |
| EP-0508665-A2 | Use of ACE inhibitors for lowering serum cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-10-14 | — | — | EP | claimed |
| EP-0482498-A2 | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1992-04-29 | — | — | EP | claimed |
| EP-0457514-A1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-11-21 | — | — | EP | claimed |
| EP-0401705-A2 | Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease | E.R. Squibb & Sons, Inc. (US) | 1990-12-12 | — | — | EP | claimed |
| US-4870106-A | THYROXINE AND 3,5,3'-TRIIODOTHYRONINE | THE HOSPITAL ATTACHED TO TIANJIN ACADEMY OF MEDICAL SCIENCES (CN) | 1989-09-26 | — | — | US | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |